enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer

   www.aol.com/news/roches-tecentriq-gets-chmp...

   Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by the CHMP for triple-negative breast cancer. Roche (RHHBY) announced that its immuno-oncology drug ...

3. Atezolizumab - Wikipedia

   en.wikipedia.org/wiki/Atezolizumab

   Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [9] [11] but discontinued for use in triple-negative breast cancer (TNBC). [12]

4. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   See the list of FDA-approved therapeutic monoclonal antibodies in the ... prostate and breast cancer: Aducanumab [10 ... Tecentriq: mab: humanized: PD-L1: Y: cancer ...

5. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   Atezolizumab (Tecentriq) is a fully humanised IgG1 (immunoglobulin 1) antibody developed by Roche Genentech. In 2016, the FDA approved atezolizumab for urothelial carcinoma and non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer.

6. New breast cancer treatment not approved for NHS use - AOL

   www.aol.com/breast-cancer-treatment-not-approved...

   For premium support please call: 800-290-4726 more ways to reach us

7. Many cancer drugs remain unproven 5 years after accelerated ...

   www.aol.com/news/many-cancer-drugs-remain...

   The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. In a new study, researchers found that most cancer drugs granted ...

8. Cancer immunotherapy - Wikipedia

   en.wikipedia.org/wiki/Cancer_immunotherapy

   Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [73] [74] but discontinued for use in triple-negative breast cancer (TNBC). [75]

9. Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

   www.aol.com/news/roches-tecentriq-gets-fda...

   Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).